| 摘要 |
The invention provides a method for reducing the level of alloantibodies in a sensitized patient awaiting kidney transplantation by administering Belimumab or an antibody that specifically binds a B-lymphocyte stimulator protein (BLyS). The invention further provides a method for reducing the risk of an allograft rejection in an allograft recipient by administering Belimumab or an antibody that specifically binds a BLyS.
|
